1-phenyl-4-benzylpiperazines; dopamine receptor subtype specific ligands
US6172229A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 11, 1999 |
| Grant date | Jan 9, 2001 |
| Priority date | — |
| Expiry date | Jan 11, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2603/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable addition salts thereof wherein: PA1 R.sub.1 is halogen or C.sub.1 -C.sub.4 alkyl; and PA1 R.sub.2 and R.sub.3 are the same or different and represent hydrogen, halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, alkylthio, hydroxy, amino, mono(C.sub.1 -C.sub.4)alkylamino, di(C.sub.1 -C.sub.4)alkylamino, or PA1 R.sub.2 and R.sub.3 together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.